NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

Show simple item record

dc.contributor.author EFSA Panel Dietetic Prod Nutr
dc.date.accessioned 2019-02-08T08:28:01Z
dc.date.available 2019-02-08T08:28:01Z
dc.date.issued 2018-01
dc.identifier.citation EFSA Panel Dietetic Prod Nutr 2018 , ' NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 ' , EFSA Journal , vol. 16 , no. 1 , 5139 . https://doi.org/10.2903/j.efsa.2018.5139 en
dc.identifier.issn 1831-4732
dc.identifier.other PURE: 121750233
dc.identifier.other PURE UUID: 407c9cfa-f25a-4b6d-9202-94c55da2ecfb
dc.identifier.other WOS: 000423808600036
dc.identifier.other ORCID: /0000-0002-9930-4009/work/53825683
dc.identifier.other Scopus: 85062069728
dc.identifier.uri http://hdl.handle.net/10138/298809
dc.description.abstract Following an application from Newtricious R&D B.V., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panelon Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to NWT-02 and a reduction of the loss of vision. The food proposed by the applicant as the subject of the health claim is NWT-02. NWT-02 is standardised by its content in lutein (>= 1.10 mg), zeaxanthin (>= 0.20 mg) and docosahexaenoic acid (DHA) (>= 170 mg). The Panel considers that the food/constituent that is the subject of the health claim, NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, is sufficiently characterised. The claimed effect proposed by the applicant is 'reduces loss of vision'. The target population proposed by the applicant is 'healthy adults over 50 years of age'. The Panel considers that a reduction of the loss of vision is a beneficial physiological effect. The applicant provided two human intervention studies for the scientific substantiation of the claim. The Panel considers that the only study from which conclusions can be drawn for the scientific substantiation of the claim did not show an effect of NWT-02 on vision. The Panel concludes that a cause and effect relationship has not been established between the consumption of NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk, and a reduction of the loss of vision. (c) 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority. en
dc.format.extent 12
dc.language.iso eng
dc.relation.ispartof EFSA Journal
dc.rights en
dc.subject NWT-02 en
dc.subject vision en
dc.subject vision acuity en
dc.subject health claim en
dc.subject BUTTERMILK en
dc.subject 416 Food Science en
dc.title NWT-02, a fixed combination of lutein, zeaxanthin and docosahexaenoic acid in egg yolk and reduction of the loss of vision : evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 en
dc.type Article
dc.description.version Peer reviewed
dc.identifier.doi https://doi.org/10.2903/j.efsa.2018.5139
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion
dc.contributor.pbl
dc.contributor.pbl
dc.contributor.pbl

Files in this item

Total number of downloads: Loading...

Files Size Format View
Panel_et_al_2018_EFSA_Journal_2.pdf 733.2Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record